In 2019, Hemanext and its research colleagues wrote the latest in a series of papers published in prestigious journals that added to the body of scientific evidence supporting the clinical potential of hypoxic RBC storage.
2019
Recent Posts
- Hemanext signs agreements with healthcare distributor in the U.A.E.
- Hemanext Inc. Announces New HCPCS Code for “Red Blood Cells, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit.”
- Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study
- AABB Science Innovation Forum Nov 2023
- Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®